UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 or 15(d) of the

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): ~~September~~November 295, 2025

MOONLAKE IMMUNOTHERAPEUTICS

(Exact Name of Registrant as Specified in Its Charter)

Cayman Islands		001-39630		98-1711963
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

Dorfstrasse 29

6300 Zug

Switzerland

(Address of ~~Principal~~principal ~~Executive~~executive ~~Offices~~offices and Zip Code)

41 415108022

(Registrant’s Telephone Number, Including Area Code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Class A ordinary share, par value $0.0001 per share		MLTX		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 81.01. ~~Other~~Entry ~~Events~~into a Material Definitive Agreement.

On ~~September~~November 285, 2025, MoonLake Immunotherapeutics (the “Company”) ~~issued~~entered ainto ~~press~~an ~~release~~underwriting ~~announcing~~agreement ~~the~~(“Underwriting Agreement”) ~~week~~with 16Leerink ~~results~~Partners ofLLC as the ~~Phase~~underwriter 3named ~~VELA-1~~therein ~~and~~(the ~~VELA-2~~“Underwriter”), ~~trials~~to ofissue ~~its~~and ~~registrational~~sell ~~global~~7,142,857 ~~program~~Class inA ~~patients~~ordinary ~~with~~shares, ~~moderate-to-severe~~par ~~hidradenitis~~value ~~suppurativa~~$0.0001 ~~The~~per ~~Company~~share ~~will~~(the ~~host a webcast today~~“Shares”), ~~Monday, September 29, 2025~~ at ~~8:00~~an ~~am,~~offering ~~Eastern~~price ~~Time,~~of to$10.50 ~~discuss~~per share (the ~~data results~~“Offering”).

AThe ~~copy~~gross ofproceeds from the ~~press~~Offering ~~release~~are ~~is filed as Exhibit~~expected ~~99.1~~ to ~~this~~be ~~Current~~$75 ~~Report~~million onbefore ~~Form~~deducting ~~8-K~~underwriting discounts and isoffering ~~incorporated by reference herein~~expenses.

The Shares described above were offered pursuant to a shelf registration statement on Form S-3 (File No. 333-274286), which became effective on September 11, 2023. A prospectus supplement dated November 5, 2025 relating to and describing the terms of the Offering was filed with the U.S. Securities and Exchange Commission on November 5, 2025. The Offering is expected to close on November 6, 2025, subject to the satisfaction of customary closing conditions.

In the Underwriting Agreement, the Company agreed to indemnify the Underwriter against certain liabilities, including liabilities under the Securities Act of 1933, as amended, or to contribute payments that the Underwriter may be required to make because of such liabilities.

A copy of the Underwriting Agreement is filed as Exhibit 1.1 and is incorporated herein by reference. The foregoing description of the Underwriting Agreement does not purport to be complete and is qualified in its entirety by reference to such exhibit.

Walkers (Cayman) LLP, Cayman counsel to the Company, has issued an opinion to the Company, dated November 5, 2025, regarding the validity of the issuance and sale of the Shares in the Offering. A copy of the opinion is filed herewith as Exhibit 5.1.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits~~. The following exhibit is being filed herewith:~~

Exhibit Number		Exhibit Title or Description
Exhibit No.		Description
99.1		Press Release, dated September 28, 2025
1.1		Underwriting Agreement, dated November 5, 2025, by and between MoonLake Immunotherapeutics and Leerink Partners LLC
5.1		Opinion of Walkers (Cayman) LLP
23.1		Consent of Walkers (Cayman) LLP (contained in Exhibit 5.1)
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	MOONLAKE IMMUNOTHERAPEUTICS
Date: September 29, 2025	By:	/s/ Matthias Bodenstedt
Date: November 5, 2025	By:	/s/ Matthias Bodenstedt
	Name:	Matthias Bodenstedt
	Title:	Chief Financial Officer

Filing Compare · MoonLake Immunotherapeutics